Halcion is the brand name for triazolam, a short acting benzodiazepine prescribed for a few days of insomnia treatment. Employers and patients who have come across it on a prescription bottle often ask whether a routine workplace drug screen will catch it. The honest answer is that a standard benzodiazepine immunoassay, the kind used in most drug test cups and dip cards, is not well suited to finding triazolam, and a negative screen does not rule out recent use. This post walks through why that is, what panel triazolam does and does not fall under, and how a lab confirms it when the question actually matters.
What Halcion is
Triazolam is a triazolobenzodiazepine, structurally related to alprazolam, approved for the short term treatment of insomnia, generally 7 to 10 days, in adults. The current prescribing information lists it as a Schedule IV controlled substance with typical adult dosing of 0.25 mg at bedtime and a maximum of 0.5 mg, with lower starting doses for geriatric patients. The drug's own label states that triazolam has a plasma elimination half life in the range of 1.5 to 5.5 hours, among the shortest of the prescription benzodiazepines, and is metabolized by the CYP3A pathway into 1-hydroxytriazolam and 4-hydroxytriazolam, which are then conjugated into glucuronides before being excreted in urine. Only small amounts of unmetabolized triazolam appear in urine at all, according to the DailyMed triazolam label. That dosing and metabolism profile, milligram doses instead of the 2 to 10 mg doses typical of diazepam, and hydroxylated metabolites instead of the nordiazepam type metabolites many screening antibodies were built around, is the reason triazolam behaves differently on a screen than other benzodiazepines. The Code of Federal Regulations list of Schedule IV substances confirms triazolam's placement as a Schedule IV controlled substance alongside other prescription benzodiazepines.
Screening immunoassay versus confirmation
Two different technologies get lumped together under "drug test," and the distinction matters here. A screening immunoassay, the chemistry inside a drug test cup, dip card, or oral fluid device, uses antibodies that bind to a target drug or metabolite and produce a color change. These antibodies are raised against a specific chemical structure, usually a metabolite common to older benzodiazepines such as diazepam and chlordiazepoxide. Triazolam's hydroxylated metabolites do not resemble that target molecule nearly as closely, so many BZO immunoassay panels have reduced sensitivity to triazolam specifically, compared with how well the same assay detects diazepam or its relatives. A clinical review of urine drug screening results in suspected poisoning cases lists triazolam by name among the benzodiazepines "likely to give false-negative results" on immunoassay based screening, alongside flunitrazepam, alprazolam, lorazepam, etizolam, brotizolam, and clothiazepam, even when the drug is present in the blood at or above therapeutic concentrations. That is a screening limitation, not proof the drug is absent.
Confirmation testing is a different method entirely. Gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS) physically separates and identifies individual molecules rather than relying on antibody binding. These methods can identify triazolam and its specific metabolites directly, which is why a confirmation test ordered because of a reported prescription, a suspected false negative, or a clinical reason can detect triazolam use even when the initial screen was negative or inconclusive. Confirmation is also the step that would catch a false positive on the opposite end, where a screen flags positive for the BZO class generally but the specific drug needs to be identified. No screening cup or card on the market performs this kind of molecular identification; it is a laboratory service.
Benzodiazepines and screen sensitivity
| Benzodiazepine | Typical adult dose | Standard BZO immunoassay sensitivity | Confirmation method |
|---|---|---|---|
| Diazepam (Valium) | 2 to 10 mg | Generally well detected; metabolites closely match assay target | GC/MS or LC/MS/MS |
| Chlordiazepoxide | 5 to 25 mg | Generally well detected | GC/MS or LC/MS/MS |
| Clonazepam (Klonopin) | 0.5 to 2 mg | Variable; some assays under detect at low cutoffs | GC/MS or LC/MS/MS |
| Alprazolam (Xanax) | 0.25 to 1 mg | Variable; low dose can fall under default cutoffs | GC/MS or LC/MS/MS |
| Lorazepam (Ativan) | 1 to 2 mg | Often reduced; cited among drugs prone to false negatives | GC/MS or LC/MS/MS |
| Triazolam (Halcion) | 0.125 to 0.5 mg | Reduced; low dose and hydroxylated metabolites limit antibody binding | GC/MS or LC/MS/MS |
The pattern across the table is consistent with the published finding, in the same clinical review of urine drug screening results, that several of the shorter acting, lower dose benzodiazepines are the ones most likely to be missed by a standard immunoassay cutoff, triazolam among them. This is also why the detection window for triazolam on a screen is short even on a good day. Given the roughly 1.5 to 5.5 hour half life, triazolam and its glucuronide metabolites typically clear the body within one to two days of a single dose, and a screening device that is already insensitive to the drug's metabolites has very little time to catch it even if it would detect a larger urinary concentration.
What panel this actually falls under
Triazolam is a benzodiazepine, so it falls under the BZO panel line on multi panel cups and dip cards, not under opiates, amphetamines, THC, cocaine, or PCP. It is worth noting for employers building a program that, per SAMHSA's drug testing resources, the federal standard for workplace testing historically centers on five drug categories, amphetamines, cocaine, marijuana, opiates, and phencyclidine, with benzodiazepines, barbiturates, and a handful of other classes offered only as additional categories employers can choose to add. That means a basic 5 panel federal style cup will not look for triazolam, or any benzodiazepine, at all; an employer has to specifically select a device with a BZO line, such as a 10 or 12 panel cup, to screen for this drug class in the first place.
Prescription documentation and the MRO
None of this is a basis for self diagnosing a result or trying to interpret a screen outside the proper review chain. If a screen is non negative for the benzodiazepine class, a certified medical review officer (MRO) is responsible for contacting the individual, confirming any current prescription with the pharmacy or prescriber, and determining whether the result is explained by legitimate medical use before any report goes to an employer. The federal procedure rules for safety sensitive testing lay out this prescription verification step explicitly, including how a verified legitimate medical explanation is handled differently from an unexplained result. Anyone prescribed Halcion should keep the prescription label or a pharmacy printout available and disclose it to the MRO if asked, rather than trying to explain it informally to a supervisor or collector. This article does not evaluate dosing, treatment duration, or whether a specific result should be considered a violation; those are clinical and MRO determinations.
What this means for buyers and programs
For labs, clinics, and employers who need to know whether a benzodiazepine panel will reliably flag every drug in that class, the honest answer is no single immunoassay cutoff catches every benzodiazepine equally well, and triazolam is one of the drugs in that class most often cited for reduced sensitivity. Programs that specifically need to detect triazolam use, rather than benzodiazepines broadly, should plan for laboratory LC/MS/MS confirmation rather than relying on a screening cutoff alone. American Screening Corporation supplies multi panel drug test cups, dip cards, and oral fluid devices with BZO detection lines, and offers lab based confirmation services for programs that need a definitive result. Related reading on this site covers the BZO panel's detection times and known gaps and how a chemically similar drug performs on the same panel in the post on whether temazepam shows up on a drug test. Clinics and distributors building out a program can review device options at the drug test cup collection, or reach the wholesale team through the wholesale portal for bulk pricing.
Frequently asked questions
Does Halcion show up on a standard drug test cup?
Only if the cup includes a BZO (benzodiazepine) line, and even then sensitivity to triazolam specifically is reduced compared with other benzodiazepines because of its low dose and hydroxylated metabolites. A basic 5 panel cup without a BZO line will not screen for it at all.
Why does triazolam get missed more than other benzodiazepines?
Triazolam is dosed in fractions of a milligram, far lower than diazepam, and its primary metabolites are hydroxylated forms rather than the nordiazepam type metabolite most screening antibodies were designed to detect. Published clinical literature lists triazolam among the benzodiazepines prone to false negative immunoassay results.
How long does Halcion stay detectable after a dose?
Triazolam has a plasma elimination half life of about 1.5 to 5.5 hours per its FDA label, so detection windows are short. Exact windows vary with dose, individual metabolism, and the test's cutoff, and there is no single number that applies to every person.
Can a lab confirm triazolam even if the screen is negative?
Yes. GC/MS or LC/MS/MS confirmation identifies the specific drug and metabolites directly rather than relying on antibody cross reactivity, and can be ordered when there is a clinical or investigative reason to look specifically for triazolam.
What should someone with a Halcion prescription do before a workplace test?
Keep the prescription label or a pharmacy printout and provide it to the medical review officer if contacted about a non negative result. The MRO, not the collection site or the employer directly, is responsible for verifying a legitimate medical explanation.
Is Halcion a controlled substance?
Yes. Triazolam is listed as a Schedule IV controlled substance under federal drug scheduling regulations, the same schedule as most other prescription benzodiazepines.
This article is general information about drug testing science and panel design, not medical or legal advice. Anyone with questions about a specific prescription, test result, or workplace policy should talk to a qualified clinician, a medical review officer, or legal counsel.
